 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12...1819202122232425262728...4142» |
- tamoxifen / Generic mfg.
[VIRTUAL] Fertility preservation for breast cancer patients before chemotherapy (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_807;
Wider implications: We systematically investigated various aspects of ovarian stimulation for oocyte retrieval in breast cancer patients undergoing fertility preservation prior to chemotherapy, our review indicated that (1) random-start controlled ovarian stimulation protocol showed comparable oocyte yields with minimal delays of referral to initiate ovarian stimulation; (2) two ovarian stimulation cycles results in higher numbers of retrieved oocytes while back-to-back and conventional two cycles showed no significant differences; (3) combinations with letrozole demonstrated a safer way over tamoxifen and anastrozole in terms of lowering estradiol level during stimulation processes; (4) in vitro maturation of immature oocytes can maximize the numbers of oocytes for cryopreservation; and (5) regarding patients’ genetic backgrounds, those with BRCA mutations have lower AMH levels, but similar in numbers of retrieved oocytes to those without BRCA mutations. Nonetheless, we look forward to higher evidence-level studies to understand the clinical relevance of these protocols for ovarian stimulation in breast cancer patients desiring fertility preservation before chemotherapy.
- tamoxifen / Generic mfg., everolimus / Generic mfg., fulvestrant / Generic mfg.
[VIRTUAL] From clinical trials to clinical practice: Real-life outcome data of everolimus and exemestane in the treatment of patients with metastatic breast cancer (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_801;
Fulvestrant was given as a third line endocrine therapy in 54 (59.3%) patients...Conclusions : Despite enrolling sicker and heavier-pretreated patients, our real-life outcome data for both efficacy and safety of exemestane and everolimus matches those reported in major clinical trials. Such results should assure clinicians and should lead to wider utilization of this oral, chemotherapy-sparing regimen.
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] A phase II proof-of-concept study of palbociclib (P) rechallenge in patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC) and clinical benefit to prior P-based treatment (BIOPER) (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_709;
P2
This strategy is currently being evaluated in the randomized phase II PALMIRA trial. Further research is ongoing to identify patient subgroups who could benefit from this treatment strategy.
- Kisqali (ribociclib) / Novartis
[VIRTUAL] Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_698;
The third interim analysis is planned in October 2020, and the updated baseline data, information on safety, digital ECG measurement using CANKADO application will be presented. $$MISSING OR BAD TABLE SPECIFICATION {6A08F088-108A-4CF1-82CE-E9E331DB5576}$$
- Arimidex (anastrozole) / AstraZeneca, Remedica
[VIRTUAL] The efficacy of a comprehensive bone health program in maintaining bone mineral density in postmenopausal women with early-stage breast cancer treated with endocrine therapy (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_643;
Such risk increases significantly with the use of AI. However, early interventions with modifiable risk factors, Vitamin-D supplements and use of bone-modifying agents can lower this risk.
- tamoxifen / Generic mfg.
[VIRTUAL] Use of a web-based decision aid to promote chemoprevention uptake among racially/ethnically diverse women at high-risk for developing breast cancer: A qualitative study (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_607;
These results emphasize the need for more tailoring of the DA based on user characteristics and a holistic approach to reducing breast cancer risk, to include information on breast cancer screening, as well as lifestyle risk factors. Next steps include incorporating feedback from this study to further enhance the DA and to optimize the modular architecture within RealRisks to include additional modules to meet the needs of diverse high-risk women.
- tamoxifen / Generic mfg.
[VIRTUAL] Dietary supplement use in a healthy eating and exercise lifestyle intervention in breast cancer survivors: The Lifestyle Exercise and Nutrition (LEAN) Study (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_581;
Our findings are indicative of the high prevalence of DS use among breast cancer survivors and the potential risk of interactions with prescribed hormonal therapy. More research is needed to test if counseling from a RD, CSO can reduce DS use and ultimately lead to better outcomes due to fewer interactions with breast cancer treatments.
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] Pre/perimenopausal (preMeno) women receiving palbociclib (PAL) for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2‒) advanced breast cancer (ABC) in a real-world setting: Treatment patterns from POLARIS (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_504;
P=N/A
The majority of preMeno pts in this real-world dataset received PAL+LET as 1L ABC treatment; PAL was primarily initiated at the recommended dose (125 mg) and was well tolerated with few dose modifications required. Clinical trial identification: Pfizer (NCT03280303)
- Arimidex (anastrozole) / AstraZeneca, Remedica
[VIRTUAL] Overall survival outcomes of combination anastrozole and fulvestrant in molecular subsets of hormone receptor-positive breast cancer (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_408;
Patients with PIK3CA, ESR1 or BRCA1/2 mutation or with HER2 overexpression/amplification historically have poor survival outcomes, but in hypothesis-generating analysis, we showed statistically similar overall survival outcomes in these patients treated with anastrozole plus fulvestrant, compared to controls without these poor prognostic features. We suggest that anastrozole plus fulvestrant should be the preferred partner with molecularly targeted agents.
- tamoxifen / Generic mfg.
[VIRTUAL] Association of OPG rs2073618 and aromatase inhibitor induced musculoskeletal symptoms (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_401;
Methods : Women with stage 0-III HR+ BC initiating adjuvant endocrine therapy (ET) with tamoxifen or an AI were enrolled in a prospective clinic-based observational cohort...78% received anastrozole, 20% letrozole and 2% exemestane...If confirmed in other cohorts, OPG genotyping may be able to identify individuals with HR+ early BC at increased risk for AIMSS during AI therapy. Alternate ET or interventions to reduce musculoskeletal symptoms may be needed for this population.
- fulvestrant / Generic mfg.
[VIRTUAL] Neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic breast cancer treated with CDK4/6 inhibitors (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_360;
The median age was 61 years [interquartile range (IQR): 61-69]. Of these, 60% were Non-Hispanic, 40% were Hispanic, 46% were Black, 19% were Caucasian and 6% were Asian.
- Votrient (pazopanib) / Novartis
[VIRTUAL] Circulating tumor cell (CTC) enumeration in a phase II trial of pazopanib in addition to endocrine therapy in patients with hormone resistant advanced breast cancer (ABC) (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_283;
P2
These results support clinical efficacy of antiangiogenic TKI in HR+ ABC and suggest benefit in hormone resistant disease. Consistently negative CTCs correlated with response and response duration.
- tamoxifen / Generic mfg., fulvestrant / Generic mfg.
[VIRTUAL] Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_268;
Patients with low sTK1 at BL may do relatively well on single agent and may not need combination ET. We speculate that patients with low sTK1 need only ET monotherapy and may not benefit from the addition of CDK4/6 or mTOR inhibitors.
- tamoxifen / Generic mfg.
[VIRTUAL] Combined analysis of the WORTH 1 and WORTH 2 studies of ipsilateral breast tumor recurrence after breast conservative surgery without radiotherapyusing the “5-mm thick slice and 5-mm free margin method” (OnDemand) - Oct 2, 2020 - Abstract #SABCS2020SABCS_203;
Both the 5- and 10-year IBTR free rates of the patients who were ≥65 at surgery and had PR positive tumors (n=136) were 98.4%. Conclusions : The findings suggest that the “5-mm thick slice and 5-mm free margin” method may be effective in selecting patients who can be treated with breast conserving surgery and hormone therapy without radiotherapy.
- paclitaxel / Generic mfg., fulvestrant / Generic mfg., cyclophosphamide intravenous / Generic mfg.
[VIRTUAL] Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106) (Channel 1) - Oct 2, 2020 - Abstract #SABCS2020SABCS_151;
P3
More effective treatments are needed for this high-risk ER+/HER2- pt population. Support: U10CA180821, U10CA180882, U24CA196171, UG1CA189856, U10CA180868 (NRG); NCI BIQSFP, BCRF, Genentech, AstraZeneca.
- Arimidex (anastrozole) / AstraZeneca, Remedica
[VIRTUAL] 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ (Channel 1) - Oct 2, 2020 - Abstract #SABCS2020SABCS_108;
No clear efficacy differences were seen between the two treatments, although the data suggests possible greater efficacy for anastrozole over tamoxifen for prevention of ER-positive breast cancers. There were some clear differences in adverse events and anastrozole may be more appropriate for some women with contraindications for tamoxifen.
- ||| miransertib (MK-7075) / Merck (MSD)
Trial termination, Combination therapy: Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole (clinicaltrials.gov) - Sep 30, 2020
P1b, N=41, Terminated, Sponsor: ArQule
There were some clear differences in adverse events and anastrozole may be more appropriate for some women with contraindications for tamoxifen. Completed --> Terminated
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: ADEPT: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (clinicaltrials.gov) - Sep 29, 2020
P2, N=375, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- [VIRTUAL] Macular changes due to aromatase inhibitors (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_684;
Both the alpha and beta oestrogen receptor subtypes are expressed and functionally active in RPE, neurosensory retina and choroid. Letrozole, a nonsteroidal aromatase inhibitor possibly breaks the blood retinal barrier by inhibiting the biosynthesis of oestrogen resulting in accumulation of the fluid in the retina.Aromatase inhibitors associated Maculopathy is a rare side effect and possibly reverses on stopping of them.
- ||| Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Enrollment change, Combination therapy: Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer (clinicaltrials.gov) - Sep 28, 2020
P2, N=17, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Letrozole, a nonsteroidal aromatase inhibitor possibly breaks the blood retinal barrier by inhibiting the biosynthesis of oestrogen resulting in accumulation of the fluid in the retina.Aromatase inhibitors associated Maculopathy is a rare side effect and possibly reverses on stopping of them. Recruiting --> Active, not recruiting | N=46 --> 17
- ||| Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Metastases: MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) - Sep 24, 2020
P3, N=463, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | N=46 --> 17 Trial completion date: Nov 2020 --> May 2021
- tamoxifen / Generic mfg.
[VIRTUAL] Efficacy and quality of life (QOL) in premenopausal Asian patients (pts) with hormone receptor–positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) treated in the MONALEESA (ML)-7 study (Channel 2) - Sep 24, 2020 - Abstract #ESMOAsia2020ESMO_Asia_25;
P3
The RIB benefit was observed irrespective of ET partner (nonsteroidal aromatase inhibitor [NSAI] or tamoxifen [TAM])...Methods Pre/perimenopausal pts (≤ 1 line of prior chemotherapy; no prior ET for ABC) who received RIB or PBO + NSAI (letrozole or anastrozole) were included in this analysis...Funding: Novartis Pharmaceuticals Corporation. Clinical trial identification: NCT02278120.
- || Arimidex (anastrozole) / AstraZeneca, Remedica
Bone aching. My joints were suddenly... all over, absolutely killing me. I tried, I really did. But I couldn’t bear it. My doctor recommended Anastrozole but I fear the same side affects will occur. Any thoughts? (Twitter) - Sep 23, 2020
- | Arimidex (anastrozole) / AstraZeneca, Remedica
آناسترازول (Anastrozole) با نام تجاری آریمیدکس (Arimidex) یک داروی ضد سرطان میباشد که برای درمان انواع خاصی از سرطان پستان در زنانی که یائسگی میباشند به کار میرود،. @merck #bleeding خیلی گشتم هیشکی نداره (Twitter) - Sep 22, 2020
- ||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
New P1 trial, Combination therapy, Metastases: DESTINY-Breast08: A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Sep 19, 2020
P1b, N=185, Not yet recruiting, Sponsor: AstraZeneca
- Arimidex (anastrozole) / AstraZeneca, Remedica
[VIRTUAL] Long Qt Associated Ventricular Tachycardia Caused by Sex Hormone Therapy (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_74;
Anastrozole is an aromatase inhibitor (ANI), used as an anti-estrogen medication in women with breast cancer or as replacement therapy for hypogonadism...ConclusionAlthough reported as safe, ANI hormone therapy can be arrhythmogenic if combined with agents that potentially affect potassium currents. We recommend QT monitoring in such patients to prevent lethal arrhythmias.
- | Arimidex (anastrozole) / AstraZeneca, Remedica, fulvestrant / Generic mfg., flutamide / Generic mfg.
Preclinical, Journal: Role of testosterone and androgen receptor in periodontal disease progression in female rats. (Pubmed Central) - Sep 16, 2020
We recommend QT monitoring in such patients to prevent lethal arrhythmias. Androgen receptor activation is an important factor in the regulation of several inflammatory markers, and its blockage significantly increases bone loss.
- |||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
New P2 trial, Combination therapy: TRIO-US B-12 TALENT: Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Sep 16, 2020
P2, N=88, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Endocrine Response in Women With Invasive Lobular Breast Cancer (clinicaltrials.gov) - Sep 16, 2020
P2, N=150, Recruiting, Sponsor: Priscilla McAuliffe
Androgen receptor activation is an important factor in the regulation of several inflammatory markers, and its blockage significantly increases bone loss. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Jul 2021
- paclitaxel / Generic mfg.
[VIRTUAL] A Case of Gastric Outlet Obstruction Due to Metastatic Breast Cancer () - Sep 15, 2020 - Abstract #ACG2020ACG_3490;
She was diagnosed with IDC6 years ago (ER+/PR-/HER2) and underwent left modified radical mastectomy with axillary lymph node dissection, followed by adjuvant endocrine therapy with anastrozole on the RxPONDER Trial...She received paclitaxel 80 mg/m2 inpatient, and was discharged home to continue weekly treatments...EUS-GJ, involves locating the jejunum via EUS from within the stomach, and then placing a dedicated biflanged Lumen-apposing metal stent (LAMS), across a newly formed fistulous tract. It is an emerging procedure to create a GJ bypass and relieve GOO without the risk of surgical bypass.
- Prolia (denosumab) / Amgen, GSK, Daiichi Sankyo, Ibrance (palbociclib) / Pfizer, Arimidex (anastrozole) / AstraZeneca, Remedica
[VIRTUAL] From Bowl to Bloodstream: A Fishy Case of Foodborne Bacterial Translocation () - Sep 15, 2020 - Abstract #ACG2020ACG_3243;
This case highlights the rare potential for foodborne bacterial translocation in immunocompromised patients and the life-threatening complications that may result. Additionally this serves as a reminder of the importance of food safety in susceptible hosts and the utility of obtaining a thorough history from all patients.
- | Ibrance (palbociclib) / Pfizer
Journal: PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance. (Pubmed Central) - Sep 9, 2020
Finally, in two independent clinical cohorts of ER positive BC, we find a strong association between high expression of PLK1 and a shorter metastases-free survival and poor response to anastrozole. In conclusion, our findings support clinical development of PLK1 inhibitors in patients with advanced CCND1-driven BC, including patients progressing on palbociclib treatment.
- ||||| bireociclib (XZP 3287) / Sihuan Pharmaceutical
New P1/2 trial: A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors (clinicaltrials.gov) - Sep 7, 2020
P1/2, N=300, Recruiting, Sponsor: Sihuan Pharmaceutical Holdings Group Ltd.
- || paclitaxel / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy. (Pubmed Central) - Sep 5, 2020
Primary squamous cell carcinoma of the breast is a very rare disease with no standard treatment approach. Our case achieved pathologic complete response after neoadjuvant chemotherapy.
- Verzenio (abemaciclib) / Eli Lilly
[VIRTUAL] MONARCH 3: Updated time to chemotherapy and disease progression after abemaciclib plus aromatase inhibitor (AI) in HR +, HER2- advanced breast cancer (ABC) (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_2188;
P3
Previously presented at ESMO 2019, FPN326P Martin M et al. Reused with permission.
- Verzenio (abemaciclib) / Eli Lilly
[VIRTUAL] Safety and efficacy of abemaciclib plus endocrine therapy in elderly patients with hormone receptor-positive / human epidermal growth factor receptor 2-negative (HR +, HER2-) advanced breast cancer: an age-specific subgroup analysis of the MONARCH 2 and 3 studies (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_2187;
P3
Despite the small number of pts aged ≥75, with potentially confounding comorbidities, safety data suggest that patient education and appropriate management of AEs, including dose adjustment and use of supportive medication for GI toxicities, could maximize abemaciclib benefit. Reused with permission 2019 SABCS®
- Verzenio (abemaciclib) / Eli Lilly
[VIRTUAL] MONARCH 3: Updated time to chemotherapy and disease progression after abemaciclib plus aromatase inhibitor (AI) in HR +, HER2- advanced breast cancer (ABC) (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1474;
P3
Previously presented at ESMO 2019, FPN326P Martin M et al. Reused with permission.
- Verzenio (abemaciclib) / Eli Lilly
[VIRTUAL] Safety and efficacy of abemaciclib plus endocrine therapy in elderly patients with hormone receptor-positive / human epidermal growth factor receptor 2-negative (HR +, HER2-) advanced breast cancer: an age-specific subgroup analysis of the MONARCH 2 and 3 studies (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1473;
P3
Despite the small number of pts aged ≥75, with potentially confounding comorbidities, safety data suggest that patient education and appropriate management of AEs, including dose adjustment and use of supportive medication for GI toxicities, could maximize abemaciclib benefit. Reused with permission 2019 SABCS®
- Verzenio (abemaciclib) / Eli Lilly
[VIRTUAL] MONARCH 3: Updated time to chemotherapy and disease progression after abemaciclib plus aromatase inhibitor (AI) in HR +, HER2- advanced breast cancer (ABC) (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_680;
P3
Previously presented at ESMO 2019, FPN326P Martin M et al. Reused with permission.
- Verzenio (abemaciclib) / Eli Lilly
[VIRTUAL] Safety and efficacy of abemaciclib plus endocrine therapy in elderly patients with hormone receptor-positive / human epidermal growth factor receptor 2-negative (HR +, HER2-) advanced breast cancer: an age-specific subgroup analysis of the MONARCH 2 and 3 studies (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_679;
P3
Despite the small number of pts aged ≥75, with potentially confounding comorbidities, safety data suggest that patient education and appropriate management of AEs, including dose adjustment and use of supportive medication for GI toxicities, could maximize abemaciclib benefit. Reused with permission 2019 SABCS®
- metformin / Generic mfg.
[VIRTUAL] A Prospective Study On Metronomic Scheduling Of Non-Chemotherapeutic Drugs In Advanced Epithelial Ovarian Cancers () - Sep 3, 2020 - Abstract #IGCS2020IGCS_690;
100 women with advanced high grade EOC who had completed standard treatment by primary / interval debulking surgery followed by adjuvant chemotherapy were randomised to either receive (study group) or not to receive (control group) the non-chemotherapeutic maintenance therapy (oral Metformin, Anastrazole, Aspirin, Atorvastatin, Vitamin-D, Injection.Zoledronic acid). The use of combination of non-chemotherapeutic drugs as maintenance therapy was found to have no significant impact on the survival or reduction of recurrences in patients with advanced epithelial ovarian cancer.
- | camizestrant (AZD9833) / AstraZeneca
Trial completion date: SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (clinicaltrials.gov) - Aug 30, 2020
P1, N=168, Recruiting, Sponsor: AstraZeneca
The use of combination of non-chemotherapeutic drugs as maintenance therapy was found to have no significant impact on the survival or reduction of recurrences in patients with advanced epithelial ovarian cancer. Trial completion date: Apr 2022 --> Mar 2023
- || Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal: Use of an aromatase inhibitor in children with congenital adrenal hyperplasia: impact of anastrozole on bone mineral density and visceral adipose tissue. (Pubmed Central) - Aug 27, 2020
Anastrozole significantly reduced bone age advancement in children with CAH and advanced bone age (>2SDs) without adverse effects on BMD or VAT. Longitudinal studies of anastrozole in children with CAH are needed to validate these findings.
- | letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica
Journal: Effect of local aromatase inhibition in endometriosis using a new chick embryo chorioallantoic membrane model. (Pubmed Central) - Aug 27, 2020
Using a new chick embryo allantoic membrane (CAM) model incorporating xenografted human endometriosis cyst, we showed that topical treatment with anastrozole reduced lesion size, although oestrogens produced by CAM female embryo blunted this effect. Xenografted human endometriosis CAM is a new efficient model for the screening of new drugs targeting endometriosis tissue.
- || Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal: In high-risk, postmenopausal women, 5 years of anastrozole reduced breast cancer incidence at 11 years. (Pubmed Central) - Aug 27, 2020
Xenografted human endometriosis CAM is a new efficient model for the screening of new drugs targeting endometriosis tissue. No abstract available
- | paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Occult metastatic thyroid cancer diagnosed during breast cancer axillary sentinel node biopsy. (Pubmed Central) - Aug 22, 2020
With improving mortality in these primary cancers, clinicians are likely to encounter this association in clinical practice. Systemic therapy for metastatic breast and thyroid cancers differ and therefore a clear diagnosis of metastasis is crucial.
- | Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer (clinicaltrials.gov) - Aug 20, 2020
P1, N=44, Not yet recruiting, Sponsor: Medical College of Wisconsin
Systemic therapy for metastatic breast and thyroid cancers differ and therefore a clear diagnosis of metastasis is crucial. Trial completion date: Jul 2024 --> Jul 2025 | Initiation date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2023 --> Jul 2024
- || everolimus / Generic mfg., exemestane / Generic mfg.
Clinical, Journal: Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane. (Pubmed Central) - Aug 19, 2020
Trial completion date: Jul 2024 --> Jul 2025 | Initiation date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2023 --> Jul 2024 Eve plus Exe remains a valid option in HR+HER2- MBC.
- || Imlygic (talimogene laherparepvec) / Amgen
Enrollment change, Trial primary completion date: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (clinicaltrials.gov) - Aug 17, 2020
P1b, N=15, Recruiting, Sponsor: University of California, San Francisco
Eve plus Exe remains a valid option in HR+HER2- MBC. N=25 --> 15 | Trial primary completion date: Dec 2020 --> Feb 2022
- || letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal: Reconsideration of the third-generation non-steroidal aromatase inhibitors in pediatrics (Pubmed Central) - Aug 14, 2020
It was not recommended that AIs be routinely used to improve adult height of adolescent boy with short stature. And more clinical evidences are needed for the safety and effectiveness of AIs prescribed in pediatrics.